...
首页> 外文期刊>Breast Cancer Research >Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
【24h】

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells

机译:逆转录-聚合酶链反应(RT-PCR)检测和表征原发性乳腺癌患者血液中的循环肿瘤细胞,并与骨髓弥散细胞进行比较

获取原文
   

获取外文期刊封面封底 >>

       

摘要

IntroductionThe role of circulating tumor cells (CTCs) in blood of primary breast cancer patients is still under investigation. We evaluated the incidence of CTCs in blood, we evaluated the correlation between CTCs and disseminated tumor cells (DTCs) in the bone marrow (BM), and we characterized CTCs for the expression of HER2, the estrogen receptor (ER) and the progesterone receptor (PR).MethodsBlood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1 and HER2 transcripts with the AdnaTest BreastCancer? (AdnaGen AG, Germany). Expression of the ER and PR was assessed in an additional RT-PCR. BM aspirates from 414 patients were analyzed for DTCs by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.ResultsDTCs were found in 107/414 patients (24%), CTCs were detected in 58/431 (13%) patients. DTCs were associated with PR status of the primary tumor (P = 0.04) and CTCs significantly correlated with nodal status (P = 0.04), ER (P = 0.05), and PR (P = 0.01). DTCs in the BM weakly correlated with CTCs (P = 0.05) in blood. Interestingly, the spread of CTCs was mostly found in triple-negative tumors (P = 0.01) and CTCs in general were mostly found to be triple-negative regardless of the ER, PR and HER2 status of the primary tumor.Conclusions(1) Due to the weak concordance between CTCs and DTCs the clinical relevance may be different. (2) The biology of the primary tumor seems to direct the spread of CTCs. (3) Since the expression profile between CTCs and the primary tumor differs, the consequence for the selection of adjuvant treatment has to be evaluated.
机译:简介循环肿瘤细胞(CTC)在原发性乳腺癌患者血液中的作用仍在研究中。我们评估了血液中CTC的发生率,评估了CTC与骨髓(BM)中的弥散性肿瘤细胞(DTC)之间的相关性,并对CTC的HER2,雌激素受体(ER)和孕激素受体的表达进行了表征方法:使用AdnaTest BreastCancer对431例原发性乳腺癌患者的血液中的EpCAM,MUC1和HER2转录本进行分析。 (德国AdnaGen AG)。在另外的RT-PCR中评估ER和PR的表达。使用泛细胞角蛋白抗体A45-B / B3通过免疫细胞化学分析了414例患者的BM抽吸物的DTC,结果在107/414例患者中发现了DTC(24%),在58/431例患者中发现了CTC。 DTC与原发肿瘤的PR状态相关(P = 0.04),而CTC与淋巴结状态(P = 0.04),ER(P = 0.05)和PR(P = 0.01)显着相关。 BM中的DTC与血液中的CTC弱相关(P = 0.05)。有趣的是,无论原发肿瘤的ER,PR和HER2状况如何,CTC的扩散多见于三阴性肿瘤(P = 0.01),而一般而言CTC大多呈三阴性。结论(1)由于CTC和DTC之间的弱一致性,临床相关性可能有所不同。 (2)原发肿瘤的生物学似乎指导了CTC的扩散。 (3)由于CTC与原发性肿瘤之间的表达特征不同,因此必须评估选择辅助治疗的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号